Display options
Cite
Gallemore RP, Wallsh J, Hudson HL, et al. Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. Clin Ophthalmol. 2017;11:223-231doi: 10.2147/OPTH.S119510.
Gallemore, R. P., Wallsh, J., Hudson, H. L., Ho, A. C., Chace, R., & Pearlman, J. (2017). Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. Clinical ophthalmology (Auckland, N.Z.), 11223-231. https://doi.org/10.2147/OPTH.S119510
Gallemore, Ron P, et al. "Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial." Clinical ophthalmology (Auckland, N.Z.) vol. 11 (2017): 223-231. doi: https://doi.org/10.2147/OPTH.S119510
Gallemore RP, Wallsh J, Hudson HL, Ho AC, Chace R, Pearlman J. Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. Clin Ophthalmol. 2017 Jan 24;11:223-231. doi: 10.2147/OPTH.S119510. eCollection 2017. PMID: 28182161; PMCID: PMC5279866.
Copy Download .nbib Format: NLM
Share it on

Clin Ophthalmol. 2017 Jan 24;11:223-231. doi: 10.2147/OPTH.S119510. eCollection 2017.

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial.

Clinical ophthalmology (Auckland, N.Z.)

Ron P Gallemore, Josh Wallsh, Henry L Hudson, Allen C Ho, Richard Chace, Joel Pearlman

Affiliations

  1. Retina Macula Institute, Torrance, CA.
  2. Retina Centers PC, Tucson, AZ.
  3. Wills Eye Institute, Philadelphia, PA.
  4. Eyesight Ophthalmic Services, Portsmouth, NH.
  5. Retinal Consultants Medical Group, Sacramento, CA, USA.

PMID: 28182161 PMCID: PMC5279866 DOI: 10.2147/OPTH.S119510

Abstract

PURPOSE: To assess whether combination therapy (CT) reduces retreatments when compared to ranibizumab monotherapy (RM), while safely maintaining similar vision outcomes.

METHODS: In this 24-month trial, patients with age-related macular degeneration (AMD) were randomized to 1) quarter-fluence or 2) half-fluence triple therapy (verteporfin photodynamic therapy [vPDT] + ranibizumab + dexamethasone), 3) half-fluence double therapy (vPDT + ranibizumab), or 4) RM. The primary outcomes were number of retreatment visits and change from baseline in visual acuity (VA) at 12 months.

RESULTS: One hundred sixty-two subjects enrolled. There were 4.0 (

CONCLUSION: CT resulted in significantly fewer retreatment visits than a RM regimen at months 12 and 24. VA results appeared similar although wide confidence intervals preclude conclusions regarding vision outcomes.

Keywords: age-related macular degeneration (AMD); combination therapy; photodynamic therapy (PDT); ranibizumab; verteporfin

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Retina. 2006 Nov-Dec;26(9):988-93 - PubMed
  2. Retina. 2007 Feb;27(2):133-40 - PubMed
  3. Am J Ophthalmol. 2009 Jul;148(1):43-58.e1 - PubMed
  4. Ophthalmology. 2013 May;120(5):1046-56 - PubMed
  5. Ophthalmology. 2007 Jun;114(6):1179-85 - PubMed
  6. N Engl J Med. 2006 Oct 5;355(14 ):1432-44 - PubMed
  7. Expert Opin Drug Saf. 2010 Jan;9(1):149-65 - PubMed
  8. Retina. 2009 Feb;29(2):133-48 - PubMed
  9. Am J Ophthalmol. 2008 Feb;145(2):239-248 - PubMed
  10. Clin Ophthalmol. 2012;6:1519-25 - PubMed
  11. Br J Ophthalmol. 2008 Dec;92 (12 ):1628-35 - PubMed
  12. N Engl J Med. 2011 May 19;364(20):1897-908 - PubMed
  13. Am J Ophthalmol. 2008 May;145(5):862-74 - PubMed
  14. Am J Ophthalmol. 2007 Apr;143(4):566-83 - PubMed
  15. N Engl J Med. 2006 Oct 5;355(14):1419-31 - PubMed
  16. Retina. 2008 May;28(5):675-81 - PubMed
  17. Br J Ophthalmol. 2010 Feb;94(2):174-9 - PubMed
  18. Ophthalmologica. 2015 ;233(2):66-73 - PubMed
  19. Ophthalmology. 2009 Jun;116(6):1225.e1 - PubMed
  20. Br J Ophthalmol. 2009 Jun;93(6):754-8 - PubMed
  21. Ophthalmology. 2009 Apr;116(4):747-55, 755.e1 - PubMed
  22. Ophthalmology. 2012 Jul;119(7):1388-98 - PubMed

Publication Types